The use of granulocyte colony– stimulating factors in a Canadian outpatient setting

Current Oncology

M. Koo²  R. Baron³  S. Fine¹  T. Gill⁴  M. Marin⁴  M. Poulin-Costello⁵  N. Mittmann² 

[1] Peel Regional Cancer Centre, Credit Valley Hospital, 2200 Eglinton Avenue West, Mississauga, ON, L5M 2N1;Health Outcomes and PharmacoEconomic (HOPE) Research Centre, Sunnybrook Research Institute, E240, 2075 Bayview Avenue, Toronto, ON, M4N 3M5;AmgenOne Amgen Center DriveMS: 28-3-AThousand Oaks, CA 91320-1799;OptumInsight5500 North Service Road, Suite 501Burlington, ON, CanadaL7L 6W6;Amgen Canada Inc., 6775 Financial Drive, Suite 100, Mississauga ON L5N 0A4

关键词: Neutropenia;    prophylaxis;    colony-stimulating factors;    outcomes;    pegfilgrastim;    filgrastim;   

DOI  :  

学科分类：肿瘤学

来源: Multimed, Inc.

【 摘 要 】

Background Data on real-life utilization of granulocyte colony–stimulating factors (g-csfs) in Canada are limited. The objective of the present study was to describe the reasons for, and the patterns of, g-csf use in selected outpatient oncology clinics in Ontario and Quebec. Methods In a retrospective longitudinal cohort study, a review of medical records from 9 Canadian oncology clinics identified patients being prescribed filgrastim (fil) and pegfilgrastim (peg). Patient characteristics, reasons for g-csf use, and treatment patterns were descriptively analyzed. Results Medical records of 395 patients initiating g-csf therapy between January 2008 and January 2009 were included. Of this population, 80% were women, and breast cancer was the predominant diagnosis (59%). The most commonly prescribed g-csf was fil (56% in Ontario and 98% in Quebec). The most frequent reason for g-csf use was primary prophylaxis (42% for both fil and peg), followed by secondary prophylaxis (37% fil, 41% peg). Those proportions varied by tumour type and chemotherapy regimen. Delayed g-csf administration (more than 1 day after the end of chemotherapy) was frequently observed for fil, but rarely reported for peg, and that finding was consistent across tumours and concurrent chemotherapy regimens. Conclusions The use of g-csf varies with the malignancy type and the provincial health care setting. The most commonly prescribed g-csf agent was fil, and most first g-csf prescriptions were for primary prophylaxis. Delays were frequently observed for patients receiving fil, but were rarely reported for those receiving peg.

【 授权许可】

Unknown